Could a vaccine stop recurrent UTIs? new trial underway

NCT ID NCT06702449

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new vaccine designed to prevent urinary tract infections (UTIs) caused by E. coli bacteria. Researchers will check safety and immune response in 448 adults aged 18-64, and then see if it works in women of the same age. Participants receive either the vaccine or a placebo, and side effects like pain or fever are monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for URINARY TRACT INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

escherichia coli infection urinary tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

URINARY TRACT INFECTIONS

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Lenexa, Kansas, 66219, United States
GSK Investigational Site
RECRUITING

Secaucus, New Jersey, 07094, United States
GSK Investigational Site
RECRUITING

Rochester, New York, 14609, United States
GSK Investigational Site
RECRUITING

Weatherford, Texas, 76086, United States
GSK Investigational Site
RECRUITING

Seattle, Washington, 98104, United States
GSK Investigational Site
RECRUITING

Wenatchee, Washington, 98801, United States
GSK Investigational Site
RECRUITING

Johannesburg, 2113, South Africa
GSK Investigational Site
RECRUITING

Soshanguve, 0152, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.